Update on the therapy of Behçet's disease

Thurayya Arayssi, A. Hamdan

Research output: Contribution to journalReview article

Abstract

Behçet's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
JournalCurrent Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2005
Externally publishedYes

Fingerprint

Musculoskeletal Diseases
Mediterranean Region
Middle East
Eye Diseases
Genetic Predisposition to Disease
Vasculitis
Age of Onset
Veins
Immune System
Therapeutics
Arteries
Outcome Assessment (Health Care)
Recurrence

Keywords

  • Behçet's disease
  • Clinical manifestations
  • Diagnosis
  • Pathogenesis
  • Randomized clinical trials
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Update on the therapy of Behçet's disease. / Arayssi, Thurayya; Hamdan, A.

In: Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents, Vol. 4, No. 3, 06.2005, p. 339-348.

Research output: Contribution to journalReview article

@article{f493542c069c4a89811da1ab8295682b,
title = "Update on the therapy of Beh{\cc}et's disease",
abstract = "Beh{\cc}et's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.",
keywords = "Beh{\cc}et's disease, Clinical manifestations, Diagnosis, Pathogenesis, Randomized clinical trials, Therapy",
author = "Thurayya Arayssi and A. Hamdan",
year = "2005",
month = "6",
doi = "10.2174/1568014054065230",
language = "English",
volume = "4",
pages = "339--348",
journal = "Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry",
issn = "1871-5230",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Update on the therapy of Behçet's disease

AU - Arayssi, Thurayya

AU - Hamdan, A.

PY - 2005/6

Y1 - 2005/6

N2 - Behçet's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

AB - Behçet's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

KW - Behçet's disease

KW - Clinical manifestations

KW - Diagnosis

KW - Pathogenesis

KW - Randomized clinical trials

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=20844434402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844434402&partnerID=8YFLogxK

U2 - 10.2174/1568014054065230

DO - 10.2174/1568014054065230

M3 - Review article

VL - 4

SP - 339

EP - 348

JO - Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

JF - Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

SN - 1871-5230

IS - 3

ER -